- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07797998
Association of Diet and IBD
Association of Nutritional Status, Dietary Inflammatory Index, and Hematological Inflammatory Biomarkers With Disease Activity in Patients With Inflammatory Bowel Disease.
Panoramica dello studio
Stato
Descrizione dettagliata
The prevalence of inflammatory bowel diseases [IBD] has risen over the past decade to become a global concern. Malnutrition is one of the major issues in patients who suffer from IBD, including both CD and UC. In published studies, approximately three-quarters of patients with active IBD have protein-energy malnutrition . It is a serious concern because it links with a higher risk of infections, weak outcomes, poor prognosis, and bad post-surgical recovery . Nutrition status in IBD plays a vital role since it can alter disease activity and affect morbidity. Not only does malnutrition affect disease activity, but the dietary inflammatory potential of the diet also affects the progression and therapeutic success in IBD patients. The dietary inflammatory potential refers to the ability of a dietary pattern or specific foods to either promote or reduce inflammation in the body. Dietary components may have anti- or pro-inflammatory potentials, which can be evaluated with indices such as the Dietary Inflammatory Index (DII). DII stands out for its particular emphasis on the connection between food consumption and the development and aggravation of inflammation. Therefore, it seems sense to assess this relationship in IBD patients. There are, however, few research on the pro-inflammatory potential of diet as determined by dietary indicators and their influence on IBD activity, and the findings are equivocal.
Inflammation and abnormalities in the immune system appear to be a critical factor in the development of IBD. Therefore, noninvasive inflammatory biomarkers may help as a noninvasive, easier accessible way to detect IBD activity state than Colonoscopy, which is the most sensitive and specific diagnostic step for diagnosing and determining the disease activity and severity.
Complete blood count (CBC)-derived inflammatory indices are inexpensive, widely available mathematical formulas. They act as reliable, non-invasive proxy markers for systemic inflammation, disease activity, and immune function by tracking the balance between innate and adaptive immune cells Therefore, in our study, we aim to assess the effect of nutritional status on IBD activity and the role of inflammatory biomarkers as a simple method to determine disease activity.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Gamal A Abd-Elbar, General Practitioner
- Numero di telefono: 201028953251
- Email: gamal.18313454@med.aun.edu.eg
Luoghi di studio
-
-
-
Asyut, Egitto
- Assiut University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients aged 18-65 years.
- patients diagnosed with either Crohn's disease or ulcerative colititis
Exclusion Criteria:
- Patients with previously identified thyroid illness.
- Patients with acute infection.
- Patients with major surgeries or recent trauma within the last 6 months.
- Patients known to have a malignancy.
- Patient with a previous history of bariatric surgery.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Nutritional Status Assessed by the Subjective Global Assessment (SGA) Score.
Lasso di tempo: baseline and up to one year
|
Nutritional status is assessed using the Subjective Global Assessment (SGA) tool.
The scale categorizes patients from A (well-nourished) to C (severely malnourished).
A higher alphabetical category (C) indicates a worse nutritional outcome.
|
baseline and up to one year
|
|
Disease Activity Assessed by the Crohn's Disease Activity Index (CDAI)..
Lasso di tempo: Baseline, Week 8, and Week 24
|
Disease activity in Crohn's disease patients is evaluated using the Crohn's Disease Activity Index (CDAI).
The theoretical score ranges from 0 to 600.
Higher scores indicate a worse outcome (greater disease severity).
|
Baseline, Week 8, and Week 24
|
|
Disease Activity in Ulcerative Colitis.
Lasso di tempo: Baseline, Week 8, and Week 24
|
Disease activity in ulcerative colitis patients is evaluated using the Mayo Score.
The score ranges from 0 to 12. Higher scores indicate a worse outcome (greater disease severity).
|
Baseline, Week 8, and Week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pearson Correlation Coefficient Between Dietary Inflammatory Index (DII) Scores and disease activity in IBD Patients.
Lasso di tempo: Baseline, Week 8, and Week 24
|
The correlation between the inflammatory potential of the diet and Crohn's disease activity will be evaluated.
Diet is assessed via the Dietary Inflammatory Index (DII) derived from a Food Frequency Questionnaire.
The DII is a continuous scale where higher scores indicate a more pro-inflammatory diet.
Disease activity is assessed via the CDAI (scale: 0-600, higher scores indicate a worse outcome).
|
Baseline, Week 8, and Week 24
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IBD2026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .